Edaravone

Note: This story was updated Jan 24, 2024, to correct that Radicava and Radicava Oral Suspension are available in Switzerland but not in other European countries. FAB122, an oral formulation of edaravone developed by Ferrer, failed to slow disease progression or extend survival in adults with amyotrophic lateral…

An into-the-nose (intranasal) formulation of edaravone — the active ingredient in the amyotrophic lateral sclerosis (ALS) medication Radicava — may enhance the medication’s ability to reach brain tissue, according to a recent study. The formulation, which was made by packaging edaravone into tiny carriers called nanoparticles, was found…

Continuous monitoring of certain biomarkers in people with amyotrophic lateral sclerosis (ALS) may inform about the risk of disease progression and the response to edaravone, according to interim data from the ongoing REFINE-ALS biomarker study. Mitsubishi Tanabe Pharma America (MTPA), the developer of edaravone, recently shared these findings…

Nearly 2,000 amyotrophic lateral sclerosis (ALS) patients in the United States have been treated with Radicava ORS (edaravone) since the oral suspension formulation became available there in May, the therapy’s U.S. marketer, Mitsubishi Tanabe Pharma America (MTPA), announced. This formulation is seen to be as equally effective as Radicava, an…

Long-term use of Radicava (edaravone) is safe and may modestly slow disease progression in people with amyotrophic lateral sclerosis (ALS), according to a small Korean study. Patients also experienced no changes in phrenic nerve function, which is required for the contraction and expansion of the diaphragm muscle. “Further…

Early treatment with Radicava (edaravone) significantly slows disability progression compared with a six-month delay, including in amyotrophic lateral sclerosis (ALS) patients with poorer lung function, according to a new analysis of a Phase 3 clinical trial. Patients switching from a placebo to Radicava after their lung function fell to…

Using the approved treatment Radicava (edaravone) in a real-world setting resulted in a similar safety profile as that reported in clinical trials, with no new safety signals identified, according to a new report. The analysis involved more than 5,000 people with amyotrophic lateral sclerosis (ALS) who received the…

Radicava ORS, an oral formulation of edaravone recently approved to treat amyotrophic lateral sclerosis (ALS) in the U.S., was safe and generally well-tolerated over almost a year of treatment in a Phase 3 clinical trial, new data highlight. The results were presented by the therapy’s developer, Mitsubishi Tanabe…

The U.S. Food and Drug Administration (FDA) has approved Mitsubishi Tanabe Pharma America (MTPA)’s oral suspension formulation of edaravone, Radicava ORS, for the treatment of amyotrophic lateral sclerosis (ALS). The oral therapy is designed to offer the same efficacy as MTPA’s Radicava (edaravone) — an FDA-approved, into-the-vein therapy…

Mitsubishi Tanabe Pharma Corporation (MTPC) is seeking approval to manufacture and market MT-1186, an oral formulation of edaravone, in Japan for amyotrophic lateral sclerosis (ALS). A similar application recently gained priority review in the U.S., which reduced regulatory review time from the standard 10 months to six months. A…